News

MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has appointed Orion Diagnostica Oy (Orion) as the exclusive distributor for the Mitomic® Prostate Test (MPT™) in Germany, Denmark, Finland, Sweden, Norway, Poland, Czech Republic, Slovakia, and Hungary.

Continue reading “MDNA Life Sciences Appoints Orion Diagnostica as Exclusive Distributor in Key European Markets for the Mitomic® Prostate Test”

MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has agreed a licensing deal with Aspire Pharma Ltd. (Aspire) in the UK for the Mitomic® Prostate Test (MPT™). On the heels of recent news that MDNA’s CE marked MPT™ Real-Time PCR kit is now commercially available, this is the first international partner to be announced by MDNA and is the start of the global roll-out of MPT™through a growing network of distribution partners.

Continue reading “MDNA Life Sciences Agrees Licensing Deal with Aspire Pharma Ltd for the Mitomic® Prostate Test in the UK”

MDNA Life Sciences has entered into an exclusive license agreement with LabCorp® (LH) to develop and commercialize a non-invasive test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

Continue reading “MDNA Life Sciences Announces Exclusive License Agreement with LabCorp®”